Tags

Type your tag names separated by a space and hit enter

Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors.
J Exp Clin Cancer Res. 2009 Feb 25; 28:27.JE

Abstract

BACKGROUND

The aim of this study is to comparatively elucidate the underlying molecular pathways and clinicopathological criteria in schistosomal bladder tumor (SBT) versus non-schistosomal bladder tumor (NSBT).

METHODS

This study explored the role of p53, p16, bcl-2, ki-67, c-myc, Rb and EGFR, by using Immunohistochemistry assay, in 45 SBT and 39 NSBT patients in comparison with 16 schistosomal chronic cystitis (SC), 28 non-schistosomal chronic cystitis (NSC), and 20 normal control (CTL) subjects. The studied markers in SBT and NSBT were correlated with different clinicopathological criteria namely, tumor histopathology, grading, invasiveness, stage, and presentation of the disease.

RESULTS

SBT was associated with high grade invasive squamous cell carcinoma (SCC) while NSBT was associated with lower grade less invasive transitional cell carcinoma (TCC). The expression of p53, bcl-2, c-myc, and EGFR was higher in SBT than in NSBT while Rb was higher in NSBT than in SBT. However, p16 and ki-67 were not different between SBT and NSBT. The profile of molecular markers in SC was similar to NSC except for EGFR which was higher in SC than in NSC. Both SC and NSC showed higher level of p53, bcl-2, ki-67, and EGFR than in CTL group while p16, Rb, and c-myc were not different. p53 was associated with high grade SCC in both SBT and NSBT. Bcl-2 was associated with high grade invasive tumors in SBT and NSBT. P16 was associated with low grade, late stage, and recurrent SBT and high grade, invasive, late stage, and recurrent NSBT. Rb was associated with SCC in SBT, invasive tumors in NSBT, and late stage and recurrent presentation in both SBT and NSBT. C-myc was associated with high grade, invasive, and late stage SBT and SCC, high grade, invasive, and late stage NSBT. EGFR was associated with invasive SCC in SBT and invasive, high grade, and late stage TCC in NSBT. ki-67 was associated with invasive SBT and high grade late stage NSBT.

CONCLUSION

SBT and NSBT showed distinct molecular profile of tumor development and progression which can be taken into consideration in fine adjusting the anti-cancer therapy for SBT and NSBT.

Authors+Show Affiliations

Microbiology Research Department, University Putra Malaysia, UPM, Serdang, Malaysia. ahmsah73@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19243595

Citation

Abdulamir, Ahmed S., et al. "Tumor Markers of Bladder Cancer: the Schistosomal Bladder Tumors Versus Non-schistosomal Bladder Tumors." Journal of Experimental & Clinical Cancer Research : CR, vol. 28, 2009, p. 27.
Abdulamir AS, Hafidh RR, Kadhim HS, et al. Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. J Exp Clin Cancer Res. 2009;28:27.
Abdulamir, A. S., Hafidh, R. R., Kadhim, H. S., & Abubakar, F. (2009). Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. Journal of Experimental & Clinical Cancer Research : CR, 28, 27. https://doi.org/10.1186/1756-9966-28-27
Abdulamir AS, et al. Tumor Markers of Bladder Cancer: the Schistosomal Bladder Tumors Versus Non-schistosomal Bladder Tumors. J Exp Clin Cancer Res. 2009 Feb 25;28:27. PubMed PMID: 19243595.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tumor markers of bladder cancer: the schistosomal bladder tumors versus non-schistosomal bladder tumors. AU - Abdulamir,Ahmed S, AU - Hafidh,Rand R, AU - Kadhim,Haider S, AU - Abubakar,Fatimah, Y1 - 2009/02/25/ PY - 2008/12/12/received PY - 2009/02/25/accepted PY - 2009/2/27/entrez PY - 2009/2/27/pubmed PY - 2009/8/27/medline SP - 27 EP - 27 JF - Journal of experimental & clinical cancer research : CR JO - J. Exp. Clin. Cancer Res. VL - 28 N2 - BACKGROUND: The aim of this study is to comparatively elucidate the underlying molecular pathways and clinicopathological criteria in schistosomal bladder tumor (SBT) versus non-schistosomal bladder tumor (NSBT). METHODS: This study explored the role of p53, p16, bcl-2, ki-67, c-myc, Rb and EGFR, by using Immunohistochemistry assay, in 45 SBT and 39 NSBT patients in comparison with 16 schistosomal chronic cystitis (SC), 28 non-schistosomal chronic cystitis (NSC), and 20 normal control (CTL) subjects. The studied markers in SBT and NSBT were correlated with different clinicopathological criteria namely, tumor histopathology, grading, invasiveness, stage, and presentation of the disease. RESULTS: SBT was associated with high grade invasive squamous cell carcinoma (SCC) while NSBT was associated with lower grade less invasive transitional cell carcinoma (TCC). The expression of p53, bcl-2, c-myc, and EGFR was higher in SBT than in NSBT while Rb was higher in NSBT than in SBT. However, p16 and ki-67 were not different between SBT and NSBT. The profile of molecular markers in SC was similar to NSC except for EGFR which was higher in SC than in NSC. Both SC and NSC showed higher level of p53, bcl-2, ki-67, and EGFR than in CTL group while p16, Rb, and c-myc were not different. p53 was associated with high grade SCC in both SBT and NSBT. Bcl-2 was associated with high grade invasive tumors in SBT and NSBT. P16 was associated with low grade, late stage, and recurrent SBT and high grade, invasive, late stage, and recurrent NSBT. Rb was associated with SCC in SBT, invasive tumors in NSBT, and late stage and recurrent presentation in both SBT and NSBT. C-myc was associated with high grade, invasive, and late stage SBT and SCC, high grade, invasive, and late stage NSBT. EGFR was associated with invasive SCC in SBT and invasive, high grade, and late stage TCC in NSBT. ki-67 was associated with invasive SBT and high grade late stage NSBT. CONCLUSION: SBT and NSBT showed distinct molecular profile of tumor development and progression which can be taken into consideration in fine adjusting the anti-cancer therapy for SBT and NSBT. SN - 1756-9966 UR - https://www.unboundmedicine.com/medline/citation/19243595/Tumor_markers_of_bladder_cancer:_the_schistosomal_bladder_tumors_versus_non_schistosomal_bladder_tumors_ L2 - https://jeccr.biomedcentral.com/articles/10.1186/1756-9966-28-27 DB - PRIME DP - Unbound Medicine ER -